We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
-27.59%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$2.52B
AUM Growth
-$1.03B
Cap. Flow
+$32.7M
Cap. Flow %
1.3%
Top 10 Hldgs %
75.05%
Holding
30
New
–
Increased
10
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$10.2M
2
INCY icon
Incyte
INCY
+$6.71M
3
SAGE
Sage Therapeutics
SAGE
+$4.4M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.91M
5
HALO icon
Halozyme
HALO
+$3.29M

Top Sells

Rank Stock Value
1
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$3.67M
2
PTCT icon
PTC Therapeutics
PTCT
+$2.08M

Sector Composition

Rank Sector Weight
1 Healthcare 86.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$361M 14.36%
3,609,298
– –
INCY icon
2
Incyte
INCY
$24.4B
$278M 11.06%
3,840,406
+90,000
+2% +$6.71M
IONS icon
3
Ionis Pharmaceuticals
IONS
$9.4B
$275M 10.91%
6,779,838
+250,000
+4% +$10.2M
GILD icon
4
Gilead Sciences
GILD
$165B
$255M 10.13%
2,774,596
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$144M 5.72%
1,034,428
– –
RDUS
6
DELISTED
Radius Health, Inc.
RDUS
$137M 5.45%
4,360,399
+88,259
+2% +$3.05M
NBIX icon
7
Neurocrine Biosciences
NBIX
$16.6B
$123M 4.91%
3,121,552
– –
MDVN
8
DELISTED
MEDIVATION, INC.
MDVN
$119M 4.72%
2,581,112
– –
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$126B
$109M 4.31%
1,365,445
– –
AGIO icon
10
Agios Pharmaceuticals
AGIO
$1.93B
$87.7M 3.49%
2,159,921
– –
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$29.3B
$74.8M 2.97%
1,191,338
+58,839
+5% +$3.91M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$80.8B
$73.9M 2.94%
205,000
– –
HALO icon
13
Halozyme
HALO
$12.2B
$69.9M 2.78%
7,379,832
+350,000
+5% +$3.29M
TSRO
14
DELISTED
TESARO, Inc.
TSRO
$54.1M 2.15%
1,229,582
– –
JUNO
15
DELISTED
Juno Therapeutics, Inc.
JUNO
$49.7M 1.98%
1,305,000
– –
NVAX icon
16
Novavax
NVAX
$1.31B
$43M 1.71%
416,500
– –
ALDR
17
DELISTED
Alder Biopharmaceuticals
ALDR
$37M 1.47%
1,510,150
– –
CEMP
18
DELISTED
Cempra, Inc.
CEMP
$35.8M 1.42%
2,041,900
+50,000
+3% +$907K
KITE
19
DELISTED
Kite Pharma, Inc.
KITE
$34.4M 1.37%
750,000
– –
ICPT
20
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$32.9M 1.31%
255,719
– –
SAGE
21
DELISTED
Sage Therapeutics
SAGE
$26.7M 1.06%
833,663
+125,000
+18% +$4.4M
ESPR
22
DELISTED
Esperion Therapeutics
ESPR
$17.1M 0.68%
1,008,542
+100,000
+11% +$1.61M
PRTA icon
23
Prothena Corp
PRTA
$450M
$14.4M 0.57%
350,000
+30,000
+9% +$1.17M
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$14.2M 0.57%
2,700,737
– –
PBYI icon
25
Puma Biotechnology
PBYI
$454M
$12.7M 0.5%
431,991
– –
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q1 2016 Portfolio in Review

As of Q1 2016, BB Biotech held 30 positions worth $2.52B, down 29% from $3.55B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Trading was light in Q1 2016: portfolio turnover was 3.3%. BB Biotech opened no new positions and exited 1, leaving the 30-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier.

  • BB Biotech added most to Ionis Pharmaceuticals in Q1 2016, an estimated $10.2M increase.
  • BB Biotech's biggest Q1 2016 reduction was PTC Therapeutics, cutting an estimated $2.08M.
  • BB Biotech fully exited Tetraphase Pharmaceuticals, Inc. in Q1 2016, selling an estimated $3.67M.
  • BB Biotech's ten largest holdings make up 75% of its $2.52B portfolio in Q1 2016.
  • BB Biotech opened 0 new positions and closed 1 in Q1 2016.
  • BB Biotech's portfolio value fell 29% quarter-over-quarter to $2.52B.

Based on BB Biotech's 13F filing for Q1 2016, filed 12 May 2016.